Evidence map›Paper›PMID 36349225›Full record

ArticleRSC chemical biology2022

Alternative design strategies to help build the enzymatic retrosynthesis toolbox.

Shelby L Hooe, Gregory A Ellis, Igor L Medintz

Abstract readEditorial
In one paragraph

Article in RSC chemical biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Progresses in Cell-Free In Vitro Evolution.Advances in biochemical engineering/biotechnology · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Shelby L HooeCenter for Bio/Molecular Science and Engineering Code 6900, U.S. Naval Research Laboratory Washington DC 20375 USA igor.medintz@nrl.navy.mil.ORCID https://orcid.org/0000-0002-6991-2273
Gregory A EllisCenter for Bio/Molecular Science and Engineering Code 6900, U.S. Naval Research Laboratory Washington DC 20375 USA igor.medintz@nrl.navy.mil.ORCID https://orcid.org/0000-0001-5559-3809
Igor L MedintzCenter for Bio/Molecular Science and Engineering Code 6900, U.S. Naval Research Laboratory Washington DC 20375 USA igor.medintz@nrl.navy.mil.ORCID https://orcid.org/0000-0002-8902-4687

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Most of the complex molecules found in nature still cannot be synthesized by current organic chemistry methods. Given the number of enzymes that exist in nature and the incredible potential of directed evolution, the field of synthetic biology contains perhaps all the necessary building blocks to bring about the realization of applied enzymatic retrosynthesis. Current thinking anticipates that enzymatic retrosynthesis will be implemented using conventional cell-based synthetic biology approaches where requisite native, heterologous, designer, and evolved enzymes making up a given multi-enzyme pathway are hosted by chassis organisms to carry out designer synthesis. In this perspective, we suggest that such an effort should not be limited by solely exploiting living cells and enzyme evolution and describe some useful yet less intensive complementary approaches that may prove especially productive in this grand scheme. By decoupling reactions from the environment of a living cell, a significantly larger portion of potential synthetic chemical space becomes available for exploration; most of this area is currently unavailable to cell-based approaches due to toxicity issues. In contrast, in a cell-free reaction a variety of classical enzymatic approaches can be exploited to improve performance and explore and understand a given enzyme's substrate specificity and catalytic profile towards non-natural substrates. We expect these studies will reveal unique enzymatic capabilities that are not accessible in living cells.

Identifiers

PMID36349225
PMCPMC9627731

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.